Indolequinone antitumour agents: correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase.

A series of indolequinones bearing a range of substituents at the (indol-2-yl)methyl position has been synthesized. The ability of these indolequinones to act as substrates for recombinant human NAD(P)H:quinone oxidoreductase (NQO1), a two-electron reductase upregulated in tumour cells, was determined, along with their toxicity to an isogenic tumour cell line pair that is differentiated as either NQO1-expressing cells (BE-NQ) or NQO1-null cells (BE-WT). Overall, the 2-substituted indolequinones were relatively poor substrates for NQO1. Hydroxymethyl groups at C-2 led to higher rates of reduction, a finding that was observed previously with 3-hydroxymethylated indolequinones. Predictably, the best substrate had an electron-withdrawing ester group at the indole-2-position. The indolequinones were generally non-toxic to both cell lines with the exception of those quinones that had methylaziridine groups at the indole-5-position. These compounds could form DNA cross-links when activated by reduction and were up to 3-fold more toxic to the BE-NQ cells than the BE-WT cells.

[1]  A. Slawin,et al.  Novel quinolinequinone antitumor agents: structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1). , 1999, Bioorganic & medicinal chemistry.

[2]  D. Ross,et al.  DT-diaphorase in activation and detoxification of quinones , 1993, Cancer and Metastasis Reviews.

[3]  D. Ross,et al.  Biochemical, cytotoxic, and genotoxic effects of ES936, a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1, in cellular systems. , 2003, Molecular pharmacology.

[4]  R. Borch,et al.  Studies on the mechanisms of activation of indolequinone phosphoramidate prodrugs. , 2003, Journal of medicinal chemistry.

[5]  K. E. Bashford,et al.  N–H Insertion reactions of rhodium carbenoids. Part 3. The development of a modified Bischler indole synthesis and a new protecting-group strategy for indoles , 2002 .

[6]  R. Borch,et al.  Design, synthesis, and biological evaluation of indolequinone phosphoramidate prodrugs targeted to DT-diaphorase. , 2002, Journal of medicinal chemistry.

[7]  H. W. Scheeren,et al.  Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release. , 2001, The Journal of organic chemistry.

[8]  L. Amzel,et al.  Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches. , 2001, Biochemistry.

[9]  R. Dorr,et al.  Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles: structure-activity relationships for cytotoxicity and antitumor activity. , 2001, Journal of medicinal chemistry.

[10]  C. Moody,et al.  Indolequinone antitumor agents: correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase. Part 2. , 2001, Journal of medicinal chemistry.

[11]  L. Amzel,et al.  Structure-based development of anticancer drugs: complexes of NAD(P)H:quinone oxidoreductase 1 with chemotherapeutic quinones. , 2001, Structure.

[12]  A. Harris,et al.  The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions. , 2000, Biochemical pharmacology.

[13]  L. Amzel,et al.  Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[14]  U. Baumann,et al.  Crystal structure of human DT-diaphorase: a model for interaction with the cytotoxic prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954). , 1999, Journal of medicinal chemistry.

[15]  I. Stratford,et al.  Bioreductive activation of a series of indolequinones by human DT-diaphorase: structure-activity relationships. , 1999, Journal of medicinal chemistry.

[16]  I. Stratford,et al.  Prodrugs for targeting hypoxic tissues: regiospecific elimination of aspirin from reduced indolequinones. , 1999, Bioorganic & medicinal chemistry letters.

[17]  D. Ross,et al.  A new screening system for NAD(P)H:quinone oxidoreductase (NQO1)-directed antitumor quinones: identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  D. Ross,et al.  Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity. , 1998, Journal of medicinal chemistry.

[19]  P. Workman,et al.  Bioreductive drugs into the next millennium. , 1998, Anti-cancer drug design.

[20]  P. Wardman,et al.  Indolequinone bioreductive drugs: kinetic factors which influence selectivity for hypoxia. , 1998, Anti-cancer drug design.

[21]  I. Stratford,et al.  Targeting hypoxia with a new generation of indolequinones. , 1998, Anti-cancer drug design.

[22]  G. Adams,et al.  Indolequinone antitumor agents: reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxoindol-3-yl)methyl derivatives and hypoxia-selective cytotoxicity in vitro. , 1998, Journal of medicinal chemistry.

[23]  C. Moody,et al.  N-H Insertion Reactions of Rhodium Carbenoids: A Modified Bischler Indole Synthesis , 1998 .

[24]  G. Adams,et al.  2-Cyclopropylindoloquinones and their analogues as bioreductively activated antitumor agents: structure-activity in vitro and efficacy in vivo. , 1997, Journal of medicinal chemistry.

[25]  C. Moody,et al.  Novel bioreductive anticancer agents based on indolequinones. , 1997, Farmaco.

[26]  C. Moody,et al.  An improved synthesis of the indolequinone anticancer agent EO9 , 1995 .

[27]  S. Danishefsky,et al.  Chemical Explorations Driven by an Enchantment With Mitomycinoids - A Twenty Year Account , 1995 .

[28]  I. Stratford,et al.  Cyclopropamitosenes, novel bioreductive anticancer agents. Synthesis, electrochemistry, and biological activity of 7-substituted cyclopropamitosenes and related indolequinones. , 1994, Journal of medicinal chemistry.

[29]  D. Ross,et al.  Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases. , 1994, Cancer research.

[30]  D. Ross,et al.  Bioactivation of quinones by DT-diaphorase, molecular, biochemical, and chemical studies. , 1994, Oncology research.

[31]  D. Reinhoudt,et al.  Reductive activation of potential antitumor mitosene compounds. , 1993, Journal of medicinal chemistry.

[32]  J F McElroy,et al.  Novel piperidine sigma receptor ligands as potential antipsychotic drugs. , 1992, Journal of medicinal chemistry.

[33]  W. Speckamp,et al.  Mitomycin analogs I. Indoloquinones as (potential) bisalkylating agents , 1987 .

[34]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[35]  Lars Ernster.  [56] DT diaphorase , 1967 .